Advertisement
A vs SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- A (Agilent Technologies) has shown notably stronger relative momentum in recent months, with its share price near its 52-week high, while SYK (Stryker Corporation) trades well below its 52-week peak.
- Agilent is a life-sciences and diagnostics instruments company, whereas Stryker is a diversified medical-technology and orthopedic device maker — two different business models within healthcare.
- Agilent has delivered accelerating revenue and earnings growth and raised its full-year outlook, while Stryker has posted strong results but faced execution headwinds from a cybersecurity disruption and a peripheral vascular supply issue.
- Stryker is the much larger business by revenue and market capitalization and carries a lower beta, indicating historically lower volatility.
- Both stocks hold an average analyst rating of "Buy," though sentiment around Stryker has cooled following recent guidance and disclosure concerns.
Introduction
Investors comparing A (Agilent Technologies) and SYK (Stryker Corporation) are effectively weighing two distinct corners of the healthcare ecosystem. Agilent supplies analytical instruments, consumables, and services to laboratories across life sciences, diagnostics, and applied chemical markets. Stryker manufactures medical and surgical technologies, including implants, robotics, and hospital equipment. Both are large-cap, profitable names with recurring-revenue characteristics, yet their growth drivers, cyclicality, and recent price behavior differ meaningfully. This stock comparison is most relevant to traders and long-term investors evaluating relative performance, market positioning, and risk-reward trade-offs between a laboratory-tools leader and a diversified device maker in the current market environment.
A Overview and Recent Performance
Agilent Technologies, headquartered in Santa Clara, California, generated approximately $6.95 billion in revenue in fiscal year 2025 and employs roughly 18,000 people. The company operates through three segments — Life Sciences and Diagnostics Markets, Agilent CrossLab (consumables and services), and Applied Markets — with a growing share of recurring revenue from consumables, services, and informatics.
In recent market activity, A has displayed strong relative performance, with the share price climbing near its 52-week high and outpacing the broader market over the past year. Recent quarters showed an accelerating trend, including a double-digit reported revenue increase in one recent quarter and solid core (organic, currency-adjusted) growth. Strength has been broad-based, led by biopharma demand, a recovery in China, growth in GLP-1-related revenue, and an ongoing instrument-replacement cycle. Management raised its full-year guidance, citing healthy, albeit dynamic, market conditions. These factors have supported positive sentiment and improving analyst expectations.
SYK Overview and Recent Performance
Stryker Corporation, based in Portage, Michigan, is a global medical-technology leader with roughly $25 billion in annual revenue and about 56,000 employees. Its business spans two reportable segments — MedSurg and Neurotechnology, and Orthopaedics — covering products such as surgical equipment, hospital beds, trauma implants, and the Mako robotic-assisted surgery platform.
Stryker's recent results have been mixed. Following a first-quarter cybersecurity disruption that constrained production, SYK rebounded with strong second-quarter sales and earnings growth, supported by record Mako installations and broad demand. However, the company narrowed rather than raised its full-year outlook, and a subsequent disclosure about persisting peripheral vascular supply problems weighed on the shares, prompting several analyst price-target reductions. Consequently, Stryker's stock has traded well below its 52-week high, reflecting cooler sentiment despite solid underlying demand and margin expansion.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a library of hundreds of available systems that collectively trade thousands of different tickers. These bots vary widely in trading style, strategy, timeframe, performance, and the set of securities they target — ranging from short-term, high-frequency approaches to longer-horizon trend-following models. Only the bots best suited to current market conditions earn a place in this featured section, helping traders filter a large universe down to a focused list. Because the selection is refreshed to reflect changing market environments, the page offers a practical starting point for investors seeking automated, data-driven approaches to names like A and SYK. Explore the Trending AI Robots to review the currently featured strategies.
Head-to-Head Comparison
The clearest contrast between these two companies is their business model and market positioning. Agilent's revenue leans on laboratory capital equipment and recurring consumables, exposing it to the cyclicality of biopharma and industrial research budgets. Stryker's revenue is driven by hospital procedures and capital equipment, with demand tied more directly to elective-surgery volumes and healthcare utilization.
On growth, both companies have posted solid recent quarters, but momentum diverges. Agilent's earnings growth has been accelerating with guidance raised, while Stryker's strong growth was tempered by narrowed guidance and lingering operational issues. In terms of scale, Stryker is roughly four times Agilent's size by revenue, and its lower beta of about 0.77 suggests historically lower volatility relative to the market, versus Agilent's beta near 1.24.
Risk profiles also differ. Agilent faces sensitivity to research-funding cycles and China exposure, while Stryker's near-term risks center on cybersecurity remediation, a vascular supply disruption, and competitive intensity in robotics. On valuation, Stryker trades at a lower forward earnings multiple, while Agilent carries a higher multiple reflecting its recent growth acceleration and stronger share-price momentum.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor A (Agilent Technologies) in the current environment. The stock exhibits more consistent upward trend strength, sits near its 52-week high, and benefits from accelerating earnings growth and a raised outlook — signals of positive momentum and improving fundamentals. In contrast, SYK (Stryker) offers greater scale, a lower beta, and a larger dividend yield, but its recent price weakness, guidance conservatism, and unresolved operational headwinds weigh on relative positioning. This assessment is probabilistic rather than definitive, reflecting trend consistency, catalyst quality, and current market positioning rather than a forecast of guaranteed future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and SYK is a Buy.
A | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 94 | |
SMR RATING 1..100 | 46 | 52 | |
PRICE GROWTH RATING 1..100 | 22 | 64 | |
P/E GROWTH RATING 1..100 | 28 | 86 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (7) in the Medical Specialties industry is in the same range as A (11) in the Biotechnology industry. This means that SYK’s stock grew similarly to A’s over the last 12 months.
SYK's Profit vs Risk Rating (94) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry. This means that SYK’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (46) in the Biotechnology industry is in the same range as SYK (52) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's Price Growth Rating (22) in the Biotechnology industry is somewhat better than the same rating for SYK (64) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
A's P/E Growth Rating (28) in the Biotechnology industry is somewhat better than the same rating for SYK (86) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
| A | SYK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 66% | N/A |
| MACD ODDS (%) | 2 days ago 61% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 53% |
| Advances ODDS (%) | 11 days ago 62% | 4 days ago 57% |
| Declines ODDS (%) | 2 days ago 63% | 2 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 70% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 48% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 3 FA rating(s) are green while SYK’s FA Score has 1 green FA rating(s).
- A’s FA Score: 3 green, 2 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 4 bearish.
- SYK’s TA Score: 5 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.56% price change this week, while SYK (@Medical/Nursing Services) price change was +1.51% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.80%. For the same industry, the average monthly price growth was +3.90%, and the average quarterly price growth was +46.85%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.19%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -2.76%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (-2.80% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-2.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.